Contact TB-500 Dr

What to write to us about

TB-500 Dr is an editorial binder of the published TB-500 and thymosin beta-4 literature, and this desk handles editorial matters only. Write to us if a citation looks wrong, a study is misread, a fragment-versus-full-length distinction is muddled, or a regulatory fact has changed and should be updated against its FDA source. We take corrections seriously and we cite our sources so they can be checked.

Some requests are simply outside this desk's remit. No line here is medical guidance, no dose is recommended, and no one's individual situation is interpreted.

What we cannot help with

There is no clinic, pharmacy, telehealth line, or supplier behind this binder. It can't tell you where to obtain TB-500, can't sell or ship anything, and can't offer dosing, protocols, or treatment guidance. Whether something is right for you is a question for a licensed healthcare professional, not a reading of the literature.

For the regulatory landscape — FDA approval status, the 503A category, and how lawful compounded access works in general — the TB-500 legal status page lays out the FDA-citable facts.

Editorial contact form

Use the form below for corrections and source queries. Tell us the page, the specific claim, and the source you believe is correct, and we will review it against the literature. A name and an email address are optional but help us follow up. This form reaches the editorial desk only and creates no clinical relationship of any kind.